•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript
What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript
Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
Genmab Stock Hits 52-Week High - Here's Why
Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
Genmab's Encouraging Oncology Data Boosts Investor Optimism
Genmab Shares Jump After Positive Cancer Study Results
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Already premium?